US20050022627A1 - Oxidation resistant treatment for metallic medical devices - Google Patents
Oxidation resistant treatment for metallic medical devices Download PDFInfo
- Publication number
- US20050022627A1 US20050022627A1 US10/818,757 US81875704A US2005022627A1 US 20050022627 A1 US20050022627 A1 US 20050022627A1 US 81875704 A US81875704 A US 81875704A US 2005022627 A1 US2005022627 A1 US 2005022627A1
- Authority
- US
- United States
- Prior art keywords
- metallic
- electrode
- medical device
- plasma
- dental
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003647 oxidation Effects 0.000 title claims description 39
- 238000007254 oxidation reaction Methods 0.000 title claims description 39
- 238000000034 method Methods 0.000 claims abstract description 23
- 230000002792 vascular Effects 0.000 claims abstract description 7
- 230000007797 corrosion Effects 0.000 claims description 27
- 238000005260 corrosion Methods 0.000 claims description 27
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 210000000988 bone and bone Anatomy 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 239000010935 stainless steel Substances 0.000 claims description 10
- 229910001220 stainless steel Inorganic materials 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 8
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 239000004053 dental implant Substances 0.000 claims description 5
- 210000003709 heart valve Anatomy 0.000 claims description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 4
- 229910052786 argon Inorganic materials 0.000 claims description 2
- 239000001307 helium Substances 0.000 claims description 2
- 229910052734 helium Inorganic materials 0.000 claims description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 2
- 229910052754 neon Inorganic materials 0.000 claims description 2
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052724 xenon Inorganic materials 0.000 claims description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 47
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 230000010287 polarization Effects 0.000 description 16
- 125000004122 cyclic group Chemical group 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 230000008569 process Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 229910045601 alloy Inorganic materials 0.000 description 6
- 239000000956 alloy Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 5
- 238000000151 deposition Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 238000002161 passivation Methods 0.000 description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 229910020018 Nb Zr Inorganic materials 0.000 description 2
- 229910000990 Ni alloy Inorganic materials 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000003851 corona treatment Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000009279 wet oxidation reaction Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006388 chemical passivation reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- -1 without limitation Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
- A61L31/088—Other specific inorganic materials not covered by A61L31/084 or A61L31/086
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/14—Plasma, i.e. ionised gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/042—Iron or iron alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/306—Other specific inorganic materials not covered by A61L27/303 - A61L27/32
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
Definitions
- the present invention relates to a process for passivating a metallic surface. Specifically, an oxidation treatment is described herein is capable of efficiently passivating a metallic medical device thereby improving the corrosion resistance of the treated device.
- the medical device is a vascular stent.
- Devices manufactured from at least one metallic material are commonly implanted within the body of patient to treat a variety of conditions.
- stents, shunts, or other mechanical scaffoldings may be inserted into an occluded region of a lumen or luminal structure to provide and maintain patency therethrough.
- metallic screws, braces, or plates may be positioned within or attached to skeletonal structures throughout the patient's body to provide support thereto.
- total joint replacement devices such as replacement hip prosthetics and replacement knee prosthetics have been used to replace incompetent natural joint systems.
- implantable metallic devices are manufactured from a variety of materials, including, stainless steel, tantalum, titanium, Nickel-Titanium alloys, shape memory alloys, super elastic alloys, low-modulus Ti—Nb—Zr alloys, and colbalt-nickel alloy steel (MP-35N). While implantable metallic devices manufactured these materials have proven useful in treating a variety of physiological conditions, a number of shortcomings associated with implantable metallic devices have been identified. For example, the extended exposure of the implanted metallic devices to bodily fluids and biological materials may result in device corrosion. As a result, the performance of the implanted device may be compromised.
- the materials used in the manufacture of implantable metallic devices generally undergo a chemical passivation process during the manufacture of the implantable device.
- the device is coated with, submerged in, or otherwise exposed to an oxidizing agent or compound.
- an oxidizing agent or compound For example, nitric acid is frequently used as an oxidizing agent when passivating stainless steel.
- free metals on the surface of the implantable device may be removed and a non-reactive protective oxide layer capable of reducing or preventing material corrosion may be formed thereon.
- the chemical passivating process has been effective in passivating implantable metallic devices, a number of shortcomings have been identified.
- the chemical passivating processes tend to be time intensive procedures typically requiring the implantable device be exposed to an oxidizing agent for 15 minutes or more.
- oxidizing agents are hazardous materials and pose a health risk to exposed workers and may result in the unwanted deposition of chemical residues on the treated device.
- the oxidation treatment described herein is capable of efficiently passivating a metallic medical device thereby improving the corrosion resistance of the treated device.
- the oxidation treatment disclosed herein reduces or eliminates the possibility of residual chemical impurities remaining on the treated device as a result of the passivating procedure.
- a method of treating a metallic medical device includes providing a metallic medical device, ionizing the media surrounding at least one electrode to produce an energized plasma proximate to the electrode, and exposing the metallic device to the plasma prior to use of the metallic device.
- a method of passivating a medical device includes providing a metallic medical device, positioning at least one electrode within an atmosphere containing at least oxygen, applying energy to the electrode, forming a plasma by ionizing the atmosphere proximate to the electrode, and exposing the metallic medical device to the plasma to produce an corrosion resistant oxidation layer thereon.
- an oxidation treatment for a metallic stent includes providing a metallic stent, forming a plasma within an atmosphere containing at least oxygen, and positioning the stent within the plasma.
- a corrosion resistant medical device comprises a metallic body and at least a corrosion resistant oxidation layer formed on the metallic body.
- FIG. 1 shows a table detailing the surface composition of stents subjected to the oxidation treatment of the present invention as compared with the surface composition of untreated control stents;
- FIG. 2 shows a table summarizing the test results of a cyclic potentiodynamic polarization tests performed on untreated control stents
- FIG. 3 shows a table summarizing the historical test results relating to cyclic potentiodynamic polarization tests performed on the untreated stents
- FIG. 4 shows a table summarizing the test results of a cyclic potentiodynamic polarization tests performed on stents treated with the oxidation treatment of the present invention
- FIG. 5 shows a graph illustrating the corrosion potential of the stents treated using an oxidation treatment disclosed herein as compared to the corrosion potential of untreated control stents;
- FIG. 6 shows a graph illustrating the cyclic polarization of the treated stent sample numbers 1 , 2 , and 3 as compared to the cyclic polarization of untreated control stent sample numbers 6 and 7 ;
- FIG. 7 shows a graph illustrating the cyclic polarization of the treated stent sample numbers 4 and 5 as compared to the cyclic polarization of untreated stent sample number 8 .
- the oxidation treatment disclosed herein may be used to passivate metallic medical devices to be used within the body of a patient, thereby improving the ability of the device to resist corrosion once implanted.
- passivation may be described as the removal of exogenous contaminants or compounds from the surface of a metallic device.
- exogenous iron or iron compounds may be removed from the surface of the item, thereby altering the surface chemistry thereof.
- the oxidation treatment disclosed herein results in formation of an oxidation layer on the surface of the item.
- the oxidation treatment of the present invention provides a metallic device substantially free of organic residues, unlike conventional passivating procedures utilizing wet chemical techniques which may result in the deposition of an organic contaminants on the implantable device.
- the oxidation treatment of the present invention may be used to passivate a variety of metallic devices used throughout the body of a patient.
- a metallic vascular stent may be subjected to the oxidation treatment disclosed herein prior to implantation with the vasculature of a patient.
- the metallic medical device may include components of a replacement joint such as a replacement ball and socket joint, a metallic heart valve, implantable screws, pins, bolts, plates, skeletonal fusion devices, spinal fusion devices, bone anchors, shunts, staples, fasteners, dental implants or devices including orthodontic braces and retainers, or other metallic devices capable of being implanted into the body of a patient.
- the oxidation treatment described herein may be used to passivate or otherwise treat a variety of medical devices used prior to, during, or following a surgical or therapeutic procedure.
- the disclosed oxidation treatment may be used to improve the corrosion resistance of retractors, retainers, couplings, scalpels, needles, forceps, dental tools or devices, bone cutters, saws, and/or other surgical or dental tools or devices.
- the present oxidation treatment may be used to passive various metals, including, without limitation, stainless steel, tantalum, titanium, Nickel-Titanium alloys, shape memory alloys, super elastic alloys, low-modulus Ti-Nb-Zr alloys, and colbalt-nickel alloy steel (MP-35N).
- the oxidation treatment of the present invention utilizes a commercially available corona discharge or corona treatment system to produce the electrochemical reaction resulting in the passivation of the metallic device.
- a voltage sufficient to ionize the surrounding environment is applied to at least one electrode.
- approximately 18 kV of direct current (DC) may be applied to the electrode thereby generating a corona discharge proximate thereto, although any voltage or current capable of creating a corona discharge may be used.
- any number of electrodes may be used in the present invention. For example, a first charged electrode may be positioned proximate to a second electrode. The first charged electrode may be separated from the second electrode by a separation gap.
- the electrodes may positioned within an air environment, although those skilled in the art will appreciate that the electrodes may be located within environments containing other materials or gases.
- the electrodes may be positioned within a field containing argon, helium, neon, or xenon.
- the application of sufficient voltage to the first charged electrode ionizes the media surrounding the electrode, for example, oxygen, thereby forming ozone (O 3 ) and producing a plasma between or proximate to the first and second electrodes.
- O 3 ozone
- the Applicants theorize the Ozone forming the plasma is capable of chemically reacting with various metals of the metallic device and resulting in the oxidation thereof.
- the metallic device may be subjected to or positioned within the ionized environment formed proximate to the electrode.
- a stainless steel device for example stainless steel 316L
- the high energy plasma generated between or proximate to at least one electrode.
- the atoms of ozone forming the plasma react with atoms of iron, nickel, and chromium within the stainless steel substrate material thereby forming or depositing a corrosive resistant oxidation layer thereon.
- the metallic device undergoing the oxidation treatment disclosed herein is maintained at an ambient or near ambient temperature during the treatment procedure.
- the metallic device treated with the method disclosed herein may be sterilized and packaged for shipment.
- the oxidation treatment disclosed herein results in the deposition of a corrosion resistant layer to the metallic device in substantially less time than presently required using a wet oxidation process.
- the metallic device may be passivated by subjecting the metallic device to the corona discharge for about 3 seconds to several minutes, although those skilled in the art will appreciate that the metallic device may be subject to the corona discharge for a considerably less or more time as desired by the manufacturer.
- the present wet passivating procedures using nitric acid typically require the metallic device be exposed to the oxiding agent for a period of 15 minutes or more.
- sample numbers 1 through 7 were exposed to a plasma created from a corona discharge device for varying lengths of times.
- sample number 1 (the untreated control sample) and treated sample numbers 2-7 underwent Electron Spectroscopy for Chemical Analysis (hereinafter ESCA) to determine the effects of the oxidation treatment on the surface composition of the stents.
- ESCA Electron Spectroscopy for Chemical Analysis
- a small diameter x-ray beam is focused across an area of each stent, thereby causing electrons to be emitted from the of each stent.
- the emitted electrons are collected and examined to determine the surface composition of the device under test.
- FIG. 1 shows the results of the ESCA testing on samples 1-7.
- the surface composition of sample number 1 included significantly higher concentrations of carbon when compared with the surface composition of the treated samples (sample numbers 2-7).
- the treated sample numbers 2-7 exhibited higher surface concentrations of nitrogen and nickel than the untreated sample 1.
- the chromium to iron ratio in the treated samples sample number 2-7) was greatly reduced as a result of the oxidation treatment when compared with the untreated sample (sample number 1), thereby producing a more corrosion-resistant device than presently available.
- sample numbers 1 through 5 were left untreated. Sample numbers 1 through 5 underwent passivation using the oxidation treatment disclosed within.
- a corona discharge device included an electrode was positioned within an oxygen environment. Approximately 18 kV of direct current electrical energy was applied to the electrode, thereby ionizing the oxygen proximate to the electrode and resulting in the creation of a ionizing plasma.
- sample numbers 1-5 were exposed to the plasma created from a corona discharge device for varying lengths of times between 5 seconds and 10 seconds. TABLE 3 SAMPLE NO. CORONA EXPOSURE TIME 1 5-10 sec. 2 5-10 sec. 3 5-10 sec. 4 5-10 sec. 5 5-10 sec. 6 0 (control) 7 0 (control) 8 0 (control)
- FIG. 2 shows a table summarizing the cyclic potentiodynamic polarization test results for the untreated samples (sample numbers 6-8).
- FIG. 3 shows historical data of potentiodynamic polarization testing of similar S670 stents manufactured by Medtronic AVE. As illustrated, the corrosion potential for the untreated samples (sample numbers 6-8) was comparable with the historical data obtained by previous potentiodynamic polarization tests performed on untreated S670 stent samples. The corrosion potential of the untreated samples (sample numbers 6-8) averaged ⁇ 108 mV, while the breakdown potential averaged 462 mV.
- FIG. 4 shows a table summarizing the cyclic potentiodynamic polarization test results for the treated samples (sample numbers 1-5).
- the breakdown potential of the treated samples (sample numbers 1-5) was consistently higher than the untreated samples (sample number 6 - 8 ).
- the potential difference i.e. the average difference between the corrosion potential and the breakdown potential (E b -Ecorr) was greater in the treated samples (sample numbers 1-5) than the untreated samples (sample numbers 6-8), thereby suggesting that the oxidation treatment had improved the corrosion resistance of the treated samples (sample numbers 1-5).
- FIGS. 5-7 graphically illustrate the effects of the oxidation treatment on the treated samples (sample numbers 1-5) as compared with the untreated samples (sample numbers 6-8).
- FIG. 5 shows the corrosion potential ((V pot /E ref )/t) of the treated samples (sample number 1 - 5 ) and the untreated samples (sample numbers 6-8). As shown, the corrosion potential of the treated samples (sample numbers 1-5)is considerably higher then the untreated samples (sample numbers 6-8).
- FIGS. 6 and 7 show the cyclic polarization ((V pot /E ref )/(A/cm 2 )) of the treated samples (sample numbers 1-5) and the untreated samples (sample numbers 6-8), More specifically, FIG.
- FIGS. 6 and 3 show the cyclic polarization of treated sample numbers 1, 2, and 3 and untreated sample numbers 6 and 7.
- FIG. 8 shows the cyclic polarization of treated sample numbers 4 and 5, and untreated sample number 8.
- the treated samples (sample numbers 1-5)exhibited a higher cyclic polarization than the untreated samples (sample numbers 6-8).
- cyclic potentiodynamic polarization test revealed a higher breakdown potential and an increased difference between the rest potential and the breakdown potential for the treated stents (sample numbers 1-5)than found in the untreated stents (sample number 6-8).
- the oxidation treatment disclosed herein reduced the treated stent's susceptibility to localized corrosion thereby improving the treated stent's resistance to corrosion.
- oxidation treatment described herein may be used to provide the user with a variety of corrosion resistant metallic medical device, including, for example, vascular stents, replacement joints, metallic heart valves, screws, pins, bolts, staples, fasteners, plates, skeletonal fusion devices, spinal fusion devices, bone anchors, shunts, staples, fasteners, dental implants, orthodontic braces, dental retainers, retractors, retainers, couplings, scalpels, needles, forceps, dental tools, surgical tools, bone cutters, and saws. Accordingly, the present invention is not limited to that precisely as shown and described in the present invention.
Abstract
A method of treating a metallic medical device is disclosed and includes providing a metallic medical device, ionizing the media surrounding at least one electrode to produce an energized plasma proximate to the electrode, and exposing the metallic device to the plasma prior to use of the metallic device. In one embodiment a vascular stent is the medical device.
Description
- The present application claims priority to U.S. provisional patent application Ser. No. 60/460,365 filed Apr. 3, 2003 the entire contents of which are incorporated herein by reference.
- The present invention relates to a process for passivating a metallic surface. Specifically, an oxidation treatment is described herein is capable of efficiently passivating a metallic medical device thereby improving the corrosion resistance of the treated device. In one embodiment of the present invention the medical device is a vascular stent.
- Devices manufactured from at least one metallic material are commonly implanted within the body of patient to treat a variety of conditions. For example, stents, shunts, or other mechanical scaffoldings may be inserted into an occluded region of a lumen or luminal structure to provide and maintain patency therethrough. In an alternate embodiment, metallic screws, braces, or plates may be positioned within or attached to skeletonal structures throughout the patient's body to provide support thereto. Recently, total joint replacement devices such as replacement hip prosthetics and replacement knee prosthetics have been used to replace incompetent natural joint systems.
- Presently, implantable metallic devices are manufactured from a variety of materials, including, stainless steel, tantalum, titanium, Nickel-Titanium alloys, shape memory alloys, super elastic alloys, low-modulus Ti—Nb—Zr alloys, and colbalt-nickel alloy steel (MP-35N). While implantable metallic devices manufactured these materials have proven useful in treating a variety of physiological conditions, a number of shortcomings associated with implantable metallic devices have been identified. For example, the extended exposure of the implanted metallic devices to bodily fluids and biological materials may result in device corrosion. As a result, the performance of the implanted device may be compromised.
- In response, the materials used in the manufacture of implantable metallic devices generally undergo a chemical passivation process during the manufacture of the implantable device. Typically, the device is coated with, submerged in, or otherwise exposed to an oxidizing agent or compound. For example, nitric acid is frequently used as an oxidizing agent when passivating stainless steel. As a result, free metals on the surface of the implantable device may be removed and a non-reactive protective oxide layer capable of reducing or preventing material corrosion may be formed thereon. While the chemical passivating process has been effective in passivating implantable metallic devices, a number of shortcomings have been identified. For example, the chemical passivating processes tend to be time intensive procedures typically requiring the implantable device be exposed to an oxidizing agent for 15 minutes or more. In addition, oxidizing agents are hazardous materials and pose a health risk to exposed workers and may result in the unwanted deposition of chemical residues on the treated device.
- Thus, in light of the foregoing, there is a need oxidation treatment for metallic medical devices capable of quickly passivating a metallic device without leaving chemical residues thereon.
- The oxidation treatment described herein is capable of efficiently passivating a metallic medical device thereby improving the corrosion resistance of the treated device. In addition, the oxidation treatment disclosed herein reduces or eliminates the possibility of residual chemical impurities remaining on the treated device as a result of the passivating procedure.
- In one embodiment, a method of treating a metallic medical device is disclosed and includes providing a metallic medical device, ionizing the media surrounding at least one electrode to produce an energized plasma proximate to the electrode, and exposing the metallic device to the plasma prior to use of the metallic device.
- In an alternate embodiment, a method of passivating a medical device is described herein and includes providing a metallic medical device, positioning at least one electrode within an atmosphere containing at least oxygen, applying energy to the electrode, forming a plasma by ionizing the atmosphere proximate to the electrode, and exposing the metallic medical device to the plasma to produce an corrosion resistant oxidation layer thereon.
- In another embodiment, an oxidation treatment for a metallic stent is disclosed and includes providing a metallic stent, forming a plasma within an atmosphere containing at least oxygen, and positioning the stent within the plasma.
- In addition, a corrosion resistant medical device is described and comprises a metallic body and at least a corrosion resistant oxidation layer formed on the metallic body.
-
FIG. 1 shows a table detailing the surface composition of stents subjected to the oxidation treatment of the present invention as compared with the surface composition of untreated control stents; -
FIG. 2 shows a table summarizing the test results of a cyclic potentiodynamic polarization tests performed on untreated control stents; -
FIG. 3 shows a table summarizing the historical test results relating to cyclic potentiodynamic polarization tests performed on the untreated stents; -
FIG. 4 shows a table summarizing the test results of a cyclic potentiodynamic polarization tests performed on stents treated with the oxidation treatment of the present invention; -
FIG. 5 shows a graph illustrating the corrosion potential of the stents treated using an oxidation treatment disclosed herein as compared to the corrosion potential of untreated control stents; -
FIG. 6 shows a graph illustrating the cyclic polarization of the treatedstent sample numbers stent sample numbers -
FIG. 7 shows a graph illustrating the cyclic polarization of the treatedstent sample numbers stent sample number 8. - The oxidation treatment disclosed herein may be used to passivate metallic medical devices to be used within the body of a patient, thereby improving the ability of the device to resist corrosion once implanted. Generally, passivation may be described as the removal of exogenous contaminants or compounds from the surface of a metallic device. When passivating a stainless steel item, for example, exogenous iron or iron compounds may be removed from the surface of the item, thereby altering the surface chemistry thereof. In addition, the oxidation treatment disclosed herein results in formation of an oxidation layer on the surface of the item. In addition to passivating metallic devices, the oxidation treatment of the present invention provides a metallic device substantially free of organic residues, unlike conventional passivating procedures utilizing wet chemical techniques which may result in the deposition of an organic contaminants on the implantable device.
- The oxidation treatment of the present invention may be used to passivate a variety of metallic devices used throughout the body of a patient. For example, a metallic vascular stent may be subjected to the oxidation treatment disclosed herein prior to implantation with the vasculature of a patient. In another embodiment, the metallic medical device may include components of a replacement joint such as a replacement ball and socket joint, a metallic heart valve, implantable screws, pins, bolts, plates, skeletonal fusion devices, spinal fusion devices, bone anchors, shunts, staples, fasteners, dental implants or devices including orthodontic braces and retainers, or other metallic devices capable of being implanted into the body of a patient. In an alternate embodiment, the oxidation treatment described herein may be used to passivate or otherwise treat a variety of medical devices used prior to, during, or following a surgical or therapeutic procedure. For example, the disclosed oxidation treatment may be used to improve the corrosion resistance of retractors, retainers, couplings, scalpels, needles, forceps, dental tools or devices, bone cutters, saws, and/or other surgical or dental tools or devices. In addition, the present oxidation treatment may be used to passive various metals, including, without limitation, stainless steel, tantalum, titanium, Nickel-Titanium alloys, shape memory alloys, super elastic alloys, low-modulus Ti-Nb-Zr alloys, and colbalt-nickel alloy steel (MP-35N).
- The oxidation treatment of the present invention utilizes a commercially available corona discharge or corona treatment system to produce the electrochemical reaction resulting in the passivation of the metallic device. A voltage sufficient to ionize the surrounding environment is applied to at least one electrode. In one embodiment, approximately 18 kV of direct current (DC) may be applied to the electrode thereby generating a corona discharge proximate thereto, although any voltage or current capable of creating a corona discharge may be used. Similarly, any number of electrodes may be used in the present invention. For example, a first charged electrode may be positioned proximate to a second electrode. The first charged electrode may be separated from the second electrode by a separation gap. The electrodes may positioned within an air environment, although those skilled in the art will appreciate that the electrodes may be located within environments containing other materials or gases. For example, the electrodes may be positioned within a field containing argon, helium, neon, or xenon. The application of sufficient voltage to the first charged electrode ionizes the media surrounding the electrode, for example, oxygen, thereby forming ozone (O3) and producing a plasma between or proximate to the first and second electrodes. Further, the Applicants theorize the Ozone forming the plasma is capable of chemically reacting with various metals of the metallic device and resulting in the oxidation thereof.
- The metallic device may be subjected to or positioned within the ionized environment formed proximate to the electrode. For example, a stainless steel device (for example stainless steel 316L) may be subjected to the high energy plasma generated between or proximate to at least one electrode. As a result, the atoms of ozone forming the plasma react with atoms of iron, nickel, and chromium within the stainless steel substrate material thereby forming or depositing a corrosive resistant oxidation layer thereon. Those skilled in the art will appreciate that the metallic device undergoing the oxidation treatment disclosed herein is maintained at an ambient or near ambient temperature during the treatment procedure. Unlike wet oxidation procedures which may result in the deposition of residual materials on the metallic device and may require additional cleaning processes, the metallic device treated with the method disclosed herein may be sterilized and packaged for shipment. In addition, those skilled in the art will appreciate that the oxidation treatment disclosed herein results in the deposition of a corrosion resistant layer to the metallic device in substantially less time than presently required using a wet oxidation process. In one embodiment, the metallic device may be passivated by subjecting the metallic device to the corona discharge for about 3 seconds to several minutes, although those skilled in the art will appreciate that the metallic device may be subject to the corona discharge for a considerably less or more time as desired by the manufacturer. In contrast, the present wet passivating procedures using nitric acid typically require the metallic device be exposed to the oxiding agent for a period of 15 minutes or more.
- A further, non-limiting illustration of the oxidation treatment disclosed herein is illustrated in the following examples.
- Seven stainless steel S670 stents manufactured by Medtronic AVE were washed for three minutes within an ultrasound bath containing 99% isopropyl alcohol (IPA). Thereafter, the seven stents were removed from the IPA bath and dried within a gaseous flow of nitrogen.
- Once dried, the scents were
number 1 through 7.Sample number 1 was left untreated.Sample numbers 2 through 7 underwent passivation using the oxidation treatment disclosed herein. A corona discharge device included an electrode was positioned within an oxygen environment. Approximately 18 kV of direct current electrical energy was applied to the electrode, thereby ionizing the oxygen proximate to the electrode and resulting in the creation of a ionizing plasma. As Table 1 shows, sample numbers 2-7 were exposed to a plasma created from a corona discharge device for varying lengths of times.TABLE 1 SAMPLE NO. CORONA EXPOSURE TIME 1 0 sec (control) 2 5 sec. 3 10 sec. 4 20 sec. 5 20 sec. (Dwell) 6 60 mm. (Dwell) 7 95 mm. (Dwell) - Following the oxidation treatment, sample number 1 (the untreated control sample) and treated sample numbers 2-7 underwent Electron Spectroscopy for Chemical Analysis (hereinafter ESCA) to determine the effects of the oxidation treatment on the surface composition of the stents. During the ESCA process, a small diameter x-ray beam is focused across an area of each stent, thereby causing electrons to be emitted from the of each stent. The emitted electrons are collected and examined to determine the surface composition of the device under test.
FIG. 1 shows the results of the ESCA testing on samples 1-7. - As shown in
FIG. 1 , the surface composition of sample number 1 (the untreated control sample) included significantly higher concentrations of carbon when compared with the surface composition of the treated samples (sample numbers 2-7). In addition, the treated sample numbers 2-7 exhibited higher surface concentrations of nitrogen and nickel than theuntreated sample 1. Furthermore, the chromium to iron ratio in the treated samples sample number 2-7) was greatly reduced as a result of the oxidation treatment when compared with the untreated sample (sample number 1), thereby producing a more corrosion-resistant device than presently available. - Eight stainless steel S670 stents manufactured by Medtronic AVE were washed for three minutes within an ultrasound bath containing 99% isopropyl alcohol (IPA). Thereafter, the eight stents were removed from the IPA bath and dried within a gaseous flow of Nitrogen.
- Once dried, the stents were
number 1 through 8. Sample numbers 6-8 were left untreated.Sample numbers 1 through 5 underwent passivation using the oxidation treatment disclosed within. A corona discharge device included an electrode was positioned within an oxygen environment. Approximately 18 kV of direct current electrical energy was applied to the electrode, thereby ionizing the oxygen proximate to the electrode and resulting in the creation of a ionizing plasma. As Table 1 shows, sample numbers 1-5 were exposed to the plasma created from a corona discharge device for varying lengths of times between 5 seconds and 10 seconds.TABLE 3 SAMPLE NO. CORONA EXPOSURE TIME 1 5-10 sec. 2 5-10 sec. 3 5-10 sec. 4 5-10 sec. 5 5-10 sec. 6 0 (control) 7 0 (control) 8 0 (control) - Thereafter, the stents were subjected to cyclic potentiodynamic corrosion testing to determine the corrosion resistance of each sample.
FIG. 2 shows a table summarizing the cyclic potentiodynamic polarization test results for the untreated samples (sample numbers 6-8).FIG. 3 shows historical data of potentiodynamic polarization testing of similar S670 stents manufactured by Medtronic AVE. As illustrated, the corrosion potential for the untreated samples (sample numbers 6-8) was comparable with the historical data obtained by previous potentiodynamic polarization tests performed on untreated S670 stent samples. The corrosion potential of the untreated samples (sample numbers 6-8) averaged −108 mV, while the breakdown potential averaged 462 mV. -
FIG. 4 shows a table summarizing the cyclic potentiodynamic polarization test results for the treated samples (sample numbers 1-5). As shown, the breakdown potential of the treated samples (sample numbers 1-5) was consistently higher than the untreated samples (sample number 6-8). In addition, the potential difference (i.e. the average difference between the corrosion potential and the breakdown potential (Eb-Ecorr)) was greater in the treated samples (sample numbers 1-5) than the untreated samples (sample numbers 6-8), thereby suggesting that the oxidation treatment had improved the corrosion resistance of the treated samples (sample numbers 1-5). -
FIGS. 5-7 graphically illustrate the effects of the oxidation treatment on the treated samples (sample numbers 1-5) as compared with the untreated samples (sample numbers 6-8).FIG. 5 shows the corrosion potential ((Vpot/Eref)/t) of the treated samples (sample number 1-5) and the untreated samples (sample numbers 6-8). As shown, the corrosion potential of the treated samples (sample numbers 1-5)is considerably higher then the untreated samples (sample numbers 6-8). Further,FIGS. 6 and 7 show the cyclic polarization ((Vpot/Eref)/(A/cm2)) of the treated samples (sample numbers 1-5) and the untreated samples (sample numbers 6-8), More specifically,FIG. 6 shows the cyclic polarization of treatedsample numbers untreated sample numbers FIG. 8 shows the cyclic polarization of treatedsample numbers untreated sample number 8. As shown inFIGS. 2 and 3 , the treated samples (sample numbers 1-5)exhibited a higher cyclic polarization than the untreated samples (sample numbers 6-8). - In light of the foregoing, cyclic potentiodynamic polarization test revealed a higher breakdown potential and an increased difference between the rest potential and the breakdown potential for the treated stents (sample numbers 1-5)than found in the untreated stents (sample number 6-8). As a result, the oxidation treatment disclosed herein reduced the treated stent's susceptibility to localized corrosion thereby improving the treated stent's resistance to corrosion.
- In closing it is understood that the embodiments of the invention disclosed herein are illustrative of the principles of the invention. In addition, those skilled in the art will appreciate that the oxidation treatment described herein may be used to provide the user with a variety of corrosion resistant metallic medical device, including, for example, vascular stents, replacement joints, metallic heart valves, screws, pins, bolts, staples, fasteners, plates, skeletonal fusion devices, spinal fusion devices, bone anchors, shunts, staples, fasteners, dental implants, orthodontic braces, dental retainers, retractors, retainers, couplings, scalpels, needles, forceps, dental tools, surgical tools, bone cutters, and saws. Accordingly, the present invention is not limited to that precisely as shown and described in the present invention.
Claims (10)
1. A method of treating a metallic medical device, comprising:
providing a metallic medical device;
ionizing the media surrounding at least one electrode to produce an energized plasma proximate to the electrode; and
exposing the metallic device to the plasma prior to use of the metallic device.
2. The method of claim 1 further comprising positioning the electrode in an atmosphere containing at least one material selected from the group consisting of Oxygen, Argon, Helium, Neon, and Xenon.
3. The method of claim 1 further comprising forming an oxidation layer a surface of the metallic device.
4. The method of claim 1 wherein the metallic device is selected from the group consisting of vascular stents, replacement joints, metallic heart valves, screws, pins, bolts, staples, fasteners, plates, skeletonal fusion devices, spinal fusion devices, bone anchors, shunts, staples, fasteners, dental implants, orthodontic braces, dental retainers, retractors, retainers, couplings, scalpels, needles, forceps, dental tools, surgical tools, bone cutters, and saws.
5. The method of passivating a medical device, comprising:
providing a metallic medical device;
positioning at least one electrode within an atmosphere containing at least Oxygen;
applying energy to the electrode;
forming a plasma by ionizing the atmosphere proximate to the electrode and
exposing the metallic medical device to the plasma to produce an corrosion resistant oxidation layer thereon.
6. The method of claim 5 wherein the metallic device is selected from the group consisting of vascular stents, replacement joints, metallic heart valves, screws, pins, bolts, staples, fasteners, plates, skeletonal fusion devices, spinal fusion devices bone anchors, shunts, staples, fasteners, dental implants, orthodontic braces, dental retainers, retractors, retainers, couplings, scalpels, needles, forceps, dental tools, surgical tools, bone cutters, and saws.
7. An oxidation treatment for a metallic stent, comprising:
providing a metallic stent;
forming a plasma within an atmosphere containing at least Oxygen; and
positioning the stent within the plasma.
8. A corrosion resistant medical device, comprising:
a metallic body; and
at least a corrosion resistant oxidation layer formed on the metallic body.
9. The device of claim 8 wherein the metallic body is manufactured from stainless steel;
10. The device of claim 8 wherein the medical device is selected from the group consisting of vascular stents, replacement joints, metallic heart valves, screws, pins, bolts, staples, fasteners, plates, skeletonal fusion devices, spinal fusion devices, bone anchors, shunts, staples, fasteners, dental implants, orthodontic braces, dental retainers, retractors, retainers, couplings, scalpels, needles, forceps, dental tools, surgical tools, bone cutters, and saws.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/818,757 US20050022627A1 (en) | 2003-04-03 | 2004-04-05 | Oxidation resistant treatment for metallic medical devices |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46036503P | 2003-04-03 | 2003-04-03 | |
US10/818,757 US20050022627A1 (en) | 2003-04-03 | 2004-04-05 | Oxidation resistant treatment for metallic medical devices |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050022627A1 true US20050022627A1 (en) | 2005-02-03 |
Family
ID=34107488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/818,757 Abandoned US20050022627A1 (en) | 2003-04-03 | 2004-04-05 | Oxidation resistant treatment for metallic medical devices |
Country Status (1)
Country | Link |
---|---|
US (1) | US20050022627A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070178129A1 (en) * | 2006-02-01 | 2007-08-02 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US20090281377A1 (en) * | 2006-04-19 | 2009-11-12 | Newell Matthew B | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US20090306779A1 (en) * | 2008-06-05 | 2009-12-10 | Alphatec Spine, Inc. | Modular anterior locking interbody cage |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
US8052744B2 (en) | 2006-09-15 | 2011-11-08 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US8057534B2 (en) | 2006-09-15 | 2011-11-15 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8080055B2 (en) | 2006-12-28 | 2011-12-20 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8128689B2 (en) | 2006-09-15 | 2012-03-06 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8303643B2 (en) | 2001-06-27 | 2012-11-06 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US8808726B2 (en) | 2006-09-15 | 2014-08-19 | Boston Scientific Scimed. Inc. | Bioerodible endoprostheses and methods of making the same |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US20180227961A1 (en) * | 2017-02-03 | 2018-08-09 | Motorola Mobility Llc | Configuration information for an inactive state |
US10422018B2 (en) | 2013-05-17 | 2019-09-24 | G. Rau Gmbh & Co. Kg | Method and device for remelting and/or remelt-alloying metallic materials, in particular Nitinol |
US20230290615A1 (en) * | 2022-03-10 | 2023-09-14 | Applied Materials, Inc. | Multilayer coating for corrosion resistance |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4818488A (en) * | 1987-02-25 | 1989-04-04 | Adir Jacob | Process and apparatus for dry sterilization of medical devices and materials |
US5938854A (en) * | 1993-05-28 | 1999-08-17 | The University Of Tennessee Research Corporation | Method and apparatus for cleaning surfaces with a glow discharge plasma at one atmosphere of pressure |
-
2004
- 2004-04-05 US US10/818,757 patent/US20050022627A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4818488A (en) * | 1987-02-25 | 1989-04-04 | Adir Jacob | Process and apparatus for dry sterilization of medical devices and materials |
US5938854A (en) * | 1993-05-28 | 1999-08-17 | The University Of Tennessee Research Corporation | Method and apparatus for cleaning surfaces with a glow discharge plasma at one atmosphere of pressure |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8303643B2 (en) | 2001-06-27 | 2012-11-06 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US20070178129A1 (en) * | 2006-02-01 | 2007-08-02 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US20090281377A1 (en) * | 2006-04-19 | 2009-11-12 | Newell Matthew B | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
US8808726B2 (en) | 2006-09-15 | 2014-08-19 | Boston Scientific Scimed. Inc. | Bioerodible endoprostheses and methods of making the same |
US8052744B2 (en) | 2006-09-15 | 2011-11-08 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US8057534B2 (en) | 2006-09-15 | 2011-11-15 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8128689B2 (en) | 2006-09-15 | 2012-03-06 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
US8080055B2 (en) | 2006-12-28 | 2011-12-20 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8715339B2 (en) | 2006-12-28 | 2014-05-06 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US20090306779A1 (en) * | 2008-06-05 | 2009-12-10 | Alphatec Spine, Inc. | Modular anterior locking interbody cage |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US10422018B2 (en) | 2013-05-17 | 2019-09-24 | G. Rau Gmbh & Co. Kg | Method and device for remelting and/or remelt-alloying metallic materials, in particular Nitinol |
US20180227961A1 (en) * | 2017-02-03 | 2018-08-09 | Motorola Mobility Llc | Configuration information for an inactive state |
US20230290615A1 (en) * | 2022-03-10 | 2023-09-14 | Applied Materials, Inc. | Multilayer coating for corrosion resistance |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050022627A1 (en) | Oxidation resistant treatment for metallic medical devices | |
Singh et al. | Corrosion degradation and prevention by surface modification of biometallic materials | |
Shabalovskaya | Surface, corrosion and biocompatibility aspects of Nitinol as an implant material | |
US4743308A (en) | Corrosion inhibition of metal alloys | |
Pound | Corrosion behavior of metallic materials in biomedical applications. I. Ti and its alloys | |
Shabalovskaya et al. | Critical overview of Nitinol surfaces and their modifications for medical applications | |
US20020092583A1 (en) | Medical devices, particularly stents, and methods for their manufacture | |
WO2005104993A2 (en) | Amorphous oxide surface film for metallic implantable devices and method for production thereof | |
Trepanier et al. | Corrosion resistance and biocompatibility of passivated NiTi | |
Lukina et al. | Fretting corrosion behavior of nitinol spinal rods in conjunction with titanium pedicle screws | |
US20040117001A1 (en) | Medical devices, particularly stents, and methods for their manufacture | |
Aroussi et al. | A Comparative Study of 316L Stainless Steel and a Titanium Alloy in an Aggressive Biological Medium. | |
JP2007006941A (en) | Medical material and its manufacturing method | |
Shih et al. | Degradation of 316L stainless steel sternal wire by steam sterilization | |
Hryniewicz et al. | Modification of nitinol biomaterial for medical applications | |
Behera | Smart applications of NiTi shape memory alloy in biomedical industries | |
RU2508130C1 (en) | Fabrication of cardio implant from titanium nickelid-based alloy with surface layer modified by ion-plasma processing | |
EP3586882B1 (en) | Antibacterial biological implant | |
EP3586883B1 (en) | Method for producing antibacterial biological implant | |
JP5535647B2 (en) | Metal implant | |
US20070083269A1 (en) | Method of producing endosseous implants or medical prostheses by means of ion implantation and endosseous implant or medical prosthesis thus obtained | |
Kwok et al. | Surface treatments of nearly equiatomic NiTi alloy (nitinol) for surgical implants | |
Shabalovskaya et al. | Bioperformance of nitinol: surface tendencies | |
Sojitra et al. | Surface enhancement and characterization of L-605 cobalt alloy cardiovascular stent by novel electrochemical treatment | |
Haider | Enhanced biocompatibility of NiTi (Nitinol) via surface treatment and alloying |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDTRONIC VASCULAR, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEN, CHENG-HAN;REEL/FRAME:014774/0869 Effective date: 20040609 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |